Phase I Clinical Trial of a Therapeutic for Gram Negative Bacteria Infection

NIH RePORTER · NIH · N01 · $2,675,212 · view on reporter.nih.gov ↗

Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic agents for the treatment of infectious disease.

Key facts

NIH application ID: 10498166
Project number: 272201500005I-0-759302100202-1
Recipient: DYNPORT VACCINE COMPANY, LLC
Principal Investigator: GRAIG SHOCKEY
Activity code: N01
Funding institute: NIH
Fiscal year: 2021
Award amount: $2,675,212
Award type: —
Project period: 2021-05-13 → 2023-01-09